etranacogene dezaparvovec · Hemgenix
Gene therapy / editing
Evidence outlook
Approved: Hemophilia B
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (1)
- Adults with severe and moderately severe hemophilia B without a history of Factor IX inhibitors (conditional marketing authorisation)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06003387 NCT06003387 · Hemophilia B Registry: NCT06003387 | 3 | Annualized Bleeding Rate (ABR) (Months 7 to 18 after CSL222 treatment) 2028-10-04 | In progress: results expected 4 Oct 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Competitive landscape
This drug's own stage for Hemophilia B: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Etranacogene Dezaparvovec (Hemgenix): this drug | Approved | Gene therapy / editing | Factor IX gene delivery (hFIX-Padua) | not yet graded | No reviewed efficacy summary in this indication | |
| REGV131-LNP1265 | Phase 1/2 | Gene therapy / editing | Factor IX | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Hemgenix (etranacogene dezaparvovec) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.